HIV Infections — Safety of and Immune System Response to an HIV Vaccine (EP HIV-1090) in HIV Infected Patients
Citation(s)
A Single Center Phase I Safety and Immunogenicity Study of Epimmune HIV-1 CTL Epitope-Based DNA Vaccine (EP HIV-1090) for Immunotherapy of HIV-1 Infected Individuals Receiving Highly Active Antiretroviral Therapy (HAART)